MoonLake Immunotherap had its Relative Strength (RS) Rating upgraded from 67 to 74 Thursday — a welcome improvement, but still short of the 80 or better score you look for.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily measures share price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners often have an RS Rating of above 80 in the early stages of their moves. See if MoonLake Immunotherap can continue to rebound and hit that benchmark.
MoonLake Immunotherap is working on a cup with handle with a 52.88 buy point. See if it can clear the breakout price in volume at least 40% above average.
The company reported 0% EPS growth in the latest quarterly report, while sales growth came in at 0%. The company is expected to report its latest performance numbers on or around Aug. 7.
The company earns the No. 250 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
